Lifesciences' vice president of clinical affairs, Heart Valve Therapy,
presents the industry perspective in a discussion with representatives
from the U.S. Food and Drug Administration, academia and industry
about clinical studies and regulatory approval for percutaneous
technology. Stanton Rowe, Edwards' corporate vice president, Advanced
Technology, will also serve as one of the discussants.
Wednesday, Oct. 24
-- Transcatheter Heart Valve Fundamentals from Science to Patient:
Edwards SAPIEN Transcatheter Heart Valve -- 7:00 a.m. to 8:00 a.m.,
Room 152A. The breakfast meeting will provide an overview of the
Edwards SAPIEN transcatheter valve's design, development and
performance in patients.
Representatives from Edwards will also be in the exhibition area at booth 5041 on level two.
About Edwards Lifesciences
Edwards Lifesciences, a leader in advanced cardiovascular disease treatments, is the number-one heart valve company in the world and the global leader in acute hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards focuses on specific cardiovascular disease states including heart valve disease, peripheral vascular disease and critical care technologies. The company's global brands, which are sold in approximately 100 countries, include Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, LifeStent, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com.
Edwards, Edwards SAPIEN, MONARC and RetroFlex are trademarks of Edwards
Lifesciences Corporation. Edwards Lifesciences, Carpentier-Edwards,
Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz are
trademarks of Edwards Lifesciences Corporation and are registered in the
United States Patent and Trademark Office. Life
|SOURCE Edwards Lifesciences Corporation|
Copyright©2007 PR Newswire.
All rights reserved